<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Nitric <z:chebi fb="177" ids="25741,29356">oxide</z:chebi> (NO) and reactive oxygen species (ROS) act independently as well as cooperatively to induce neuronal <z:hpo ids='HP_0011420'>death</z:hpo> in <z:hpo ids='HP_0011009'>acute</z:hpo> <z:e sem="disease" ids="C1112108" disease_type="Disease or Syndrome" abbrv="">neurological disorders</z:e> </plain></SENT>
<SENT sid="1" pm="."><plain>Inhibition of neuronal nitric <z:chebi fb="177" ids="25741,29356">oxide</z:chebi> synthase (nNOS) and inhibition of <z:chebi fb="23" ids="18059">lipid</z:chebi> peroxidation induced by ROS have both been proposed as neuroprotective strategies in <z:hpo ids='HP_0001297'>stroke</z:hpo> and trauma </plain></SENT>
<SENT sid="2" pm="."><plain>Recently, in our laboratory, the combination of the two strategies was found to be synergistic in reducing neuronal damage </plain></SENT>
<SENT sid="3" pm="."><plain>Here, we report that BN 80933 [(S)-N-[4-[4-[(3,4-dihydro-6-hydroxy-2, 5,7, 8-tetramethyl-2H-1-<z:chebi fb="0" ids="22727">benzopyran</z:chebi>-2-yl)<z:chebi fb="1" ids="23019">carbonyl</z:chebi>]-1-piperazinyl]<z:chebi fb="1" ids="30396">phenyl</z:chebi>]-2- thiophenecarboximidamide], a compound that combines potent <z:chebi fb="11" ids="22586">antioxidant</z:chebi> and selective nNOS inhibitory properties in vitro, affords remarkable neuronal protection in vivo </plain></SENT>
<SENT sid="4" pm="."><plain>Intravenous administration of BN 80933 significantly reduced brain damage induced by head trauma in mice, global <z:e sem="disease" ids="C0022116" disease_type="Disease or Syndrome" abbrv="">ischemia</z:e> in gerbils, and transient focal <z:e sem="disease" ids="C0022116" disease_type="Disease or Syndrome" abbrv="">ischemia</z:e> in rats </plain></SENT>
<SENT sid="5" pm="."><plain>Treatment with BN 80933 (0.3-10 mg/kg) significantly reduced <z:mpath ids='MPATH_124'>infarct</z:mpath> volume (&gt;60% protection) and enhanced behavioral recovery in rats subjected to transient (2-h) middle cerebral <z:mp ids='MP_0006134'>artery occlusion</z:mp> and 48-h or 7-day reperfusion </plain></SENT>
<SENT sid="6" pm="."><plain>Furthermore, treatment with BN 80933 commencing up to 8 h after the <z:hpo ids='HP_0003674'>onset</z:hpo> of <z:e sem="disease" ids="C0022116" disease_type="Disease or Syndrome" abbrv="">ischemia</z:e> resulted in a significant improvement of neurological outcome </plain></SENT>
<SENT sid="7" pm="."><plain><z:hpo ids='HP_0000001'>All</z:hpo> these results indicate that BN 80933 represents a class of potentially useful therapeutic agents for the treatment of <z:hpo ids='HP_0001297'>stroke</z:hpo> or trauma and possibly <z:e sem="disease" ids="C0524851" disease_type="Disease or Syndrome" abbrv="">neurodegenerative disorders</z:e> that involve both NO and ROS </plain></SENT>
</text></document>